MS vaccine same platform as Covid vaccines.. relieves already existing symptoms

[Lazarus]

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis

Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register..., … show all … , Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., Only registered and activated users can see links., Click Here To Register... Only registered and activated users can see links., Click Here To Register..., AND Only registered and activated users can see links., Click Here To Register...show fewer
SCIENCE • 8 Jan 2021 • Vol 371, Issue 6525 • pp. 145-153 • Only registered and activated users can see links., Click Here To Register...
Only registered and activated users can see links., Click Here To Register...
Metrics

Total Downloads5,268

• Last 6 Months6,001
• Last 12 Months6,001

Total Citations51

• Last 6 Months23
• Last 12 Months48

Only registered and activated users can see links., Click Here To Register...Precision therapy for immune tolerance

Autoimmune diseases, such as multiple sclerosis (MS), result from a breach of immunological self-tolerance and tissue damage by autoreactive T lymphocytes. Current treatments can cause systemic immune suppression and side effects such as increased risk of infections. Krienke et al. designed a messenger RNA vaccine strategy that lacks adjuvant activity and delivers MS autoantigens into lymphoid dendritic cells.

This approach expands a distinct type of antigen-specific effector regulatory T cell that suppresses autoreactivity against targeted autoantigens and promotes bystander suppression of autoreactive T cells against other myelin-specific autoantigens. In mouse models of MS, the vaccine delayed the onset and reduced the severity of established disease without showing overt symptoms of general immune suppression.
Science, this issue p. Only registered and activated users can see links., Click Here To Register...

Anstract
The ability to control autoreactive T cells without inducing systemic immune suppression is the major goal for treatment of autoimmune diseases. The key challenge is the safe and efficient delivery of pharmaceutically well-defined antigens in a noninflammatory context. Here, we show that systemic delivery of nanoparticle-formulated 1 methylpseudouridine-modified messenger RNA (m1Ψ mRNA) coding for disease-related autoantigens results in antigen presentation on splenic CD11c⁺ antigen-presenting cells in the absence of costimulatory signals. In several mouse models of multiple sclerosis, the disease is suppressed by treatment with such m1Ψ mRNA. The treatment effect is associated with a reduction of effector T cells and the development of regulatory T cell (T_reg cell) populations. Notably, these T_reg cells execute strong bystander immunosuppression and thus improve disease induced by cognate and noncognate autoantigens.

[agate]

Thank you for posting this. Anything published in Science could be fairly significant, and this research just might lead to something useful for us. Let's hope.

[Parsi]

Thanks for posting,
Lazarus.